{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:46Z","timestamp":1793814046162,"version":"4.6.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171197"],"award-info":[{"award-number":["82171197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Bay Laboratory Open Project","award":["SZBL2020090501014"],"award-info":[{"award-number":["SZBL2020090501014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Extracellular \u03b2-amyloid plaques and intracellular neurofibrillary tau tangles are the primary hallmarks of Alzheimer's disease. \u03b2-Amyloid pathology can be directly quantified by positron emission tomography imaging or indirectly by measuring the decrease of cerebrospinal fluid \u03b2-amyloid42\/\u03b2-amyloid40 ratio. Although these two \u03b2-amyloid biomarkers may be considered interchangeable, they sometimes show discordance, particularly in early stage of Alzheimer's disease. Individuals with cerebrospinal fluid \u03b2-amyloid positive only or \u03b2-amyloid positron emission tomography positive only may be at early amyloidosis stage compared to those who are cerebrospinal fluid \u03b2-amyloid negative and \u03b2-amyloid positron emission tomography negative orcerebrospinal fluid \u03b2-amyloid positive and \u03b2-amyloid positron emission tomography positive. Besides, \u03b2-amyloid pathology may play an initiating role in Alzheimer's disease onset, leading to subsequent tau increases. However, it is still unclear whether individuals with different \u03b2-amyloid pathways have distinct spatial patterns of cortical tau tangles in early amyloidosis stage. In this study, we analyzed 238 cognitively unimpaired and 77 mild cognitive impairment individuals with concurrent (interval of acquisition &amp;lt;1 year) 18F-flortaucipir tau positron emission tomography, \u03b2-amyloid (18F-florbetapir or 18F-florbetaben) positron emission tomography and cerebrospinal fluid \u03b2-amyloid42 and \u03b2-amyloid40 and cerebrospinal fluid p-Tau181 and divided them into four different cerebrospinal fluid\/positron emission tomography groups based on the abnormal status of cerebrospinal fluid \u03b2-amyloid42\/\u03b2-amyloid40 (cerebrospinal fluid\u00b1) and \u03b2-amyloid positron emission tomography (\u00b1). We determined the cortical regions with significant tau elevations of different cerebrospinal fluid\/positron emission tomography groups and investigated the region-wise and voxel-wise associations of tau positron emission tomography images with cerebrospinal fluid \u03b2-amyloid42\/\u03b2-amyloid40, \u03b2-amyloid positron emission tomography and cerebrospinal fluid p-Tau\/\u03b2-amyloid40 in early (cerebrospinal fluid positive\/positron emission tomography negative and cerebrospinal fluid negative\/positron emission tomography positive) and late (cerebrospinal fluid positive\/positron emission tomography positive) amyloidosis stages. By compared to the cerebrospinal fluid negative\/positron emission tomography negative individuals (Ref) without evidence of tau increase measured by cerebrospinal fluid or positron emission tomography, cerebrospinal fluid positive\/positron emission tomography negative individuals showed higher tau in entorhinal but not in BraakIII\/IV and BraakV\/VI, whereas cerebrospinal fluid negative\/positron emission tomography positive individuals had significant tau elevations in BraakV\/VI but not in entorhinal and BraakIII\/IV. In contrast, cerebrospinal fluid positive\/positron emission tomography positive individuals showed significant tau increases in all the cortical regions than the Ref group. The voxel-wise analyses provided further evidence that lower cerebrospinal fluid \u03b2-amyloid42\/\u03b2-amyloid40 was associated with higher tau in entorhinal, whilst higher \u03b2-amyloid positron emission tomography was related to higher tau in BraakV\/VI regions in early amyloidosis stage. Both lower cerebrospinal fluid \u03b2-amyloid42\/\u03b2-amyloid40 and higher \u03b2-amyloid positron emission tomography were correlated with tau aggregation in all the Braak stages regions in late amyloidosis stage. These findings provide novel insights into the spatial patterns of cortical tau tangles in different amyloidosis stages of Alzheimer's disease, suggesting cerebrospinal fluid \u03b2-amyloid and \u03b2-amyloid positron emission tomography discordant groups may have distinct characteristics of cortical tau tangles in early amyloidosis stage.<\/jats:p>","DOI":"10.1093\/braincomms\/fcac084","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T11:39:23Z","timestamp":1648553963000},"source":"Crossref","is-referenced-by-count":13,"title":["\u03b2-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns"],"prefix":"10.1093","volume":"4","author":[{"given":"Chenyang","family":"Jiang","sequence":"first","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen 518107, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Xie","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, China-Japan Friendship Hospital, 2 Yinghuayuan Dongjie, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3671-0445","authenticated-orcid":false,"given":"Hongbo","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-0865","authenticated-orcid":false,"given":"Tengfei","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, China"},{"name":"Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen 518055, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"3","key":"2022041810385478000_fcac084-B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"2022041810385478000_fcac084-B2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"issue":"8","key":"2022041810385478000_fcac084-B3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.biopsych.2020.06.029","article-title":"Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer\u2019s disease pathophysiology","volume":"89","author":"Guo","year":"2021","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2022041810385478000_fcac084-B4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2967\/jnumed.116.176115","article-title":"Predicting regional pattern of longitudinal \u03b2-amyloid accumulation by baseline PET","volume":"58","author":"Guo","year":"2017","journal-title":"J Nucl Med"},{"issue":"11","key":"2022041810385478000_fcac084-B5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jalz.2018.05.013","article-title":"Rate of \u03b2-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials","volume":"14","author":"Guo","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"issue":"14","key":"2022041810385478000_fcac084-B6","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","article-title":"Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults","volume":"94","author":"Guo","year":"2020","journal-title":"Neurology"},{"issue":"15","key":"2022041810385478000_fcac084-B7","doi-asserted-by":"crossref","first-page":"e2075","DOI":"10.1212\/WNL.0000000000010596","article-title":"Association of CSF A\u03b2, amyloid PET, and cognition in cognitively unimpaired elderly adults","volume":"95","author":"Guo","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"2022041810385478000_fcac084-B8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","article-title":"Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42\/A\u03b21-40 ratio \u2013 a cross-validation study against amyloid PET","volume":"139","author":"Pannee","year":"2016","journal-title":"J Neurochem"},{"issue":"3","key":"2022041810385478000_fcac084-B9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: Better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2022041810385478000_fcac084-B10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13195-019-0561-5","article-title":"PET and CSF amyloid-\u03b2 status are differently predicted by patient features: Information from discordant cases","volume":"11","author":"Reimand","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2022041810385478000_fcac084-B11","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"issue":"11","key":"2022041810385478000_fcac084-B12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/acn3.51195","article-title":"Amyloid-\u03b2 PET and CSF in an autopsy-confirmed cohort","volume":"7","author":"Reimand","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"2022041810385478000_fcac084-B13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","article-title":"Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study","volume":"139","author":"Leuzy","year":"2016","journal-title":"Brain"},{"issue":"2","key":"2022041810385478000_fcac084-B14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"12","key":"2022041810385478000_fcac084-B15","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2","key":"2022041810385478000_fcac084-B16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-170327","article-title":"The cerebrospinal fluid A\u03b21\u201342\/A\u03b21\u201340 ratio improves concordance with amyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting","volume":"60","author":"Niemantsverdriet","year":"2017","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"11","key":"2022041810385478000_fcac084-B17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"2022041810385478000_fcac084-B18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13195-015-0159-5","article-title":"Diagnostic value of cerebrospinal fluid A\u03b2 ratios in preclinical Alzheimer\u2019s disease","volume":"7","author":"Adamczuk","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2022041810385478000_fcac084-B19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","article-title":"Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging","volume":"12","author":"Doecke","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2022041810385478000_fcac084-B20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-019-0532-x","article-title":"Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences","volume":"11","author":"de Wilde","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"2022041810385478000_fcac084-B21","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"2022041810385478000_fcac084-B22","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/s41380-020-00950-w","article-title":"Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-\u03b2 positivity","volume":"26","author":"Sala","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"1","key":"2022041810385478000_fcac084-B23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","article-title":"Use of amyloid-PET to determine cutpoints for CSF markers","volume":"86","author":"Zwan","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"2022041810385478000_fcac084-B24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"issue":"5","key":"2022041810385478000_fcac084-B25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamaneurol.2014.4829","article-title":"Nonlinear association between Cerebrospinal fluid and florbetapir F-18 \u03b2-amyloid measures across the spectrum of Alzheimer disease","volume":"72","author":"Toledo","year":"2015","journal-title":"JAMA Neurol"},{"key":"2022041810385478000_fcac084-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2016.03.025","article-title":"NIA-AA staging of preclinical Alzheimer disease: Discordance and concordance of CSF and imaging biomarkers","volume":"44","author":"Vos","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"11","key":"2022041810385478000_fcac084-B27","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"2022041810385478000_fcac084-B28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000163927","article-title":"PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid \u03b2-amyloid in mild cognitive impairment","volume":"26","author":"Koivunen","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8-9","key":"2022041810385478000_fcac084-B29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"6","key":"2022041810385478000_fcac084-B30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"2022041810385478000_fcac084-B31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-132561","article-title":"Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort","volume":"41","author":"Zwan","year":"2014","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"19","key":"2022041810385478000_fcac084-B32","doi-asserted-by":"crossref","first-page":"e2648","DOI":"10.1212\/WNL.0000000000010739","article-title":"Association of amyloid-\u03b2 CSF\/PET discordance and tau load 5 years later","volume":"95","author":"Reimand","year":"2020","journal-title":"Neurology"},{"issue":"19","key":"2022041810385478000_fcac084-B33","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1523\/JNEUROSCI.0485-18.2018","article-title":"Subthreshold amyloid predicts tau deposition in aging","volume":"38","author":"Leal","year":"2018","journal-title":"J Neurosci"},{"issue":"5","key":"2022041810385478000_fcac084-B34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/brain\/awx046","article-title":"Association between tau deposition and antecedent amyloid-\u03b2 accumulation rates in normal and early symptomatic individuals","volume":"140","author":"Tosun","year":"2017","journal-title":"Brain"},{"issue":"8","key":"2022041810385478000_fcac084-B35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"2022041810385478000_fcac084-B36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-020-00665-8","article-title":"Normalization of CSF pTau measurement by A\u03b240 improves its performance as a biomarker of Alzheimer\u2019s disease","volume":"12","author":"Guo","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"2022041810385478000_fcac084-B37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaneurol.2020.3921","article-title":"Association of initial \u03b2-Amyloid levels with subsequent flortaucipir positron emission tomography changes in persons without cognitive impairment","volume":"78","author":"Knopman","year":"2021","journal-title":"JAMA Neurol"},{"issue":"4","key":"2022041810385478000_fcac084-B38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2022041810385478000_fcac084-B39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"issue":"577","key":"2022041810385478000_fcac084-B40","doi-asserted-by":"crossref","first-page":"eabc0655","DOI":"10.1126\/scitranslmed.abc0655","article-title":"The cortical origin and initial spread of medial temporal tauopathy in Alzheimer\u2019s disease assessed with positron emission tomography","volume":"13","author":"Sanchez","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"2022041810385478000_fcac084-B41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Ann Neurol"},{"issue":"7","key":"2022041810385478000_fcac084-B42","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","article-title":"Relationship between amyloid and tau levels and its impact on tau spreading","volume":"48","author":"Dor\u00e9","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2022041810385478000_fcac084-B43","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"issue":"3","key":"2022041810385478000_fcac084-B44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"2022041810385478000_fcac084-B45","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","article-title":"An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest","volume":"31","author":"Desikan","year":"2006","journal-title":"Neuroimage"},{"issue":"4","key":"2022041810385478000_fcac084-B46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.114.148981","article-title":"Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios","volume":"56","author":"Landau","year":"2015","journal-title":"J Nucl Med"},{"key":"2022041810385478000_fcac084-B47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","article-title":"Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease","volume":"157","author":"Maass","year":"2017","journal-title":"Neuroimage"},{"issue":"7","key":"2022041810385478000_fcac084-B48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mcn.2018.12.004","article-title":"Fluid and PET biomarkers for amyloid pathology in Alzheimer\u2019s disease","volume":"97","author":"Cohen","year":"2019","journal-title":"Mol Cell Neurosci"},{"issue":"16","key":"2022041810385478000_fcac084-B49","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci Adv"},{"issue":"4","key":"2022041810385478000_fcac084-B50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","article-title":"Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated Tau and AV1451 positron emission tomography","volume":"77","author":"Meyer","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"2022041810385478000_fcac084-B51","doi-asserted-by":"crossref","first-page":"e896","DOI":"10.1212\/WNL.0000000000005064","article-title":"In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease","volume":"90","author":"Day","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"2022041810385478000_fcac084-B52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"12","key":"2022041810385478000_fcac084-B53","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1002\/acn3.51237","article-title":"Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer\u2019s disease","volume":"7","author":"Chen","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2022041810385478000_fcac084-B54","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"2022041810385478000_fcac084-B55","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal tau PET in ageing and Alzheimer\u2019s disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"issue":"23","key":"2022041810385478000_fcac084-B56","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","article-title":"Associations of Amyloid, Tau, and Neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"2022041810385478000_fcac084-B57","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1093\/brain\/awz268","article-title":"The bivariate distribution of amyloid-\u03b2 and tau: Relationship with established neurocognitive clinical syndromes","volume":"142","author":"Jack","year":"2019","journal-title":"Brain"},{"issue":"3","key":"2022041810385478000_fcac084-B58","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awy347","article-title":"Plasma tau\/amyloid-\u03b21\u201342 ratio predicts brain tau deposition and neurodegeneration in Alzheimer\u2019s disease","volume":"142","author":"Park","year":"2019","journal-title":"Brain"},{"issue":"8","key":"2022041810385478000_fcac084-B59","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/brain\/awz162","article-title":"White matter hyperintensities: Relationship to amyloid and tau burden","volume":"142","author":"Graff-Radford","year":"2019","journal-title":"Brain"},{"issue":"11","key":"2022041810385478000_fcac084-B60","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/WNL.0000000000005124","article-title":"Tau-negative amnestic dementia masquerading as Alzheimer disease dementia","volume":"90","author":"Botha","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"2022041810385478000_fcac084-B61","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"2022041810385478000_fcac084-B62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2022041810385478000_fcac084-B63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jalz.2019.08.201","article-title":"Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer\u2019s disease","volume":"16","author":"Ossenkoppele","year":"2020","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"2022041810385478000_fcac084-B64","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1212\/WNL.0000000000011081","article-title":"Topographic distribution of Amyloid-\u03b2, Tau, and Atrophy in patients with behavioral\/dysexecutive Alzheimer disease","volume":"96","author":"Therriault","year":"2021","journal-title":"Neurology"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcac084\/43205248\/fcac084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/2\/fcac084\/43388682\/fcac084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/2\/fcac084\/43388682\/fcac084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:40:14Z","timestamp":1650278414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcac084\/6561429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcac084","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,1]]},"article-number":"fcac084"}}